CD274 and neoplasm: Preclinical data showed that the addition of trilaciclib prior to chemotherapy plus ICI regimens, including both PD‐L1 and PD‐1 inhibitors, enhanced antitumour response and OS through the modulation of T‐cell proliferation and the tumour immune microenvironment, and increased effector function.18, 20, 50